<DOC>
	<DOCNO>NCT02040428</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness EVARREST™ Fibrin Sealant Patch adjunct hemostasis cardiovascular surgery .</brief_summary>
	<brief_title>The Fibrin Pad CV Phase III Study</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Subjects ≥18 year age , require elective urgent , open aortic surgical procedure utilize cardiopulmonary bypass . Subjects Japan ≥18 &lt; 20 year age require consent subject 's legal representative Subjects must willing participate study provide write informed consent . Presence appropriate Target Bleeding Site ( TBS ) along anastomotic suture line , involve synthetic aortic graft , identify intraoperatively investigator ; Subjects know intolerance blood product one component study product unwilling receive blood product ; Exposure another investigational drug device clinical trial within 30 day prior surgery anticipated 60 day follow period surgery . Female subject pregnant nursing . TBS large defect visible artery vein injure vascular wall require repair maintenance vessel patency would persistent exposure EVARREST™ Fibrin Sealant Patch blood flow and/or pressure absorption product ; TBS major arterial bleed require suture mechanical ligation ; TBS involve expand polytetrafluoroethylene ( ePTFE ) graft TBS within actively infected field ; Bleeding site , around , proximity foramen bone , area bony confine ; Subjects intraoperative finding identify investigator may preclude conduct study procedure ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Fibrin Sealant</keyword>
	<keyword>Hemostatics</keyword>
	<keyword>Coagulants</keyword>
</DOC>